Payment overview · 2025
General Payments
$1,381.47
46 reported records · 19 companies
Healthcare provider profile · identity verified
Mary Beth Wiles, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BLAIRSVILLE, GA · NPI 1407863285
Verified facts
What the public records show
CMS Open Payments records show Mary Beth Wiles, MD received $1,381.47 in general payments during 2025 across 46 reported records.
Novo Nordisk Inc accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $275.68 | 20.0% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $237.05 | 17.2% | 6 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $159.45 | 11.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $103.47 | 7.5% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $91.08 | 6.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.62 | 4.8% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $64.64 | 4.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.39 | 3.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.41 | 3.4% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.52 | 3.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.91 | 3.0% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $40.56 | 2.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.25 | 2.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.03 | 2.0% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.30 | 1.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.57 | 1.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $20.46 | 1.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.02 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.06 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,381.47 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $258.66 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $237.05 | 6 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $159.45 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $103.47 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $91.08 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.62 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $64.64 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.39 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.39 | 3 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| ADACEL Normalized: adacel |
Biological | SANOFI PASTEUR INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 44 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 344 | 90 |
| Omeprazole | Omeprazole | 210 | 53 |
| Lisinopril | Lisinopril | 201 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 68 |
| Potassium Chloride | Potassium Chloride | 189 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 166 | 47 |
| Ezetimibe | Ezetimibe | 148 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 52 |
| Losartan Potassium | Losartan Potassium | 125 | 42 |
| Gabapentin | Gabapentin | 118 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 34 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 103 | 103 |
| Allopurinol | Allopurinol | 97 | 27 |
| Metformin Hcl | Metformin Hcl | 96 | 31 |
| Furosemide | Furosemide | 94 | 29 |
| Trazodone Hcl | Trazodone Hcl | 94 | 34 |
| Famotidine | Famotidine | 90 | 31 |
| Metformin Hcl Er | Metformin Hcl | 88 | 30 |
| Spironolactone | Spironolactone | 88 | 24 |
| Buspirone Hcl | Buspirone Hcl | 87 | 29 |
| Baclofen | Baclofen | 86 | 27 |
| Simvastatin | Simvastatin | 84 | 23 |
| Donepezil Hcl | Donepezil Hcl | 83 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 30 |
| Sertraline Hcl | Sertraline Hcl | 82 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 19 |
| Alendronate Sodium | Alendronate Sodium | 70 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 18 |
| Carvedilol | Carvedilol | 67 | 19 |
| Eliquis | Apixaban | 66 | 19 |
| Bupropion Xl | Bupropion Hcl | 63 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 63 | 45 |
| Montelukast Sodium | Montelukast Sodium | 60 | 20 |
| Atenolol | Atenolol | 58 | 15 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 55 | 54 |
| Estradiol | Estradiol | 54 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 52 | 18 |
| Celecoxib | Celecoxib | 50 | 17 |
| Azelastine Hcl | Azelastine Hcl | 46 | 15 |
| Synthroid | Levothyroxine Sodium | 46 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 16 |
| Gemtesa | Vibegron | 44 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Prednisone | Prednisone | 29 | 16 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 20 |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 12 | suppressed |
| Repatha Pushtronex | Evolocumab | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,381.47 · 46 records | Novo Nordisk Inc | ADACEL, AIRSUPRA, BodyGuardian, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, Fibroscan, GEMTESA, JARDIANCE, KISUNLA, Kerendia, Korlym, LEQVIO, Leqembi, MENQUADFI, MOUNJARO, OTEZLA, Ozempic, REBYOTA, REPATHA, REZDIFFRA, Rybelsus, TZIELD, Tymlos, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error